Amgen’s Anti-Anemia Drug OKd for Swiss Sale
Johnson & Johnson said it has received approval to start selling in Switzerland the anti-anemia drug erythropoetin developed by Amgen in Thousand Oaks.
Johnson & Johnson is licensed by Amgen to sell the drug in Europe under the name EPREX, with Amgen receiving about 10% of the net sales. Amgen is seeking approval from the Food and Drug Administration to sell the drug domestically under the name Epogen.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
